Tests IB-T101 injection in adults with advanced kidney cancer
Tests IB-T101 injection in adults with advanced clear cell kidney cancer.
Plain-language title generated from the registry record
Registry title: IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 1
Where in China
- Tongji Hospital, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Grit Biotechnology
- Trial code
- NCT06819293
- Record updated
- 14 April 2026
- Original description
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinomaRead full original descriptionShow less
A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Inclusion: Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol; Age ≥18 years old; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Expected survival time of ≥ 3 months.
Exclusion: Have experienced myocardial infarction or unstable angina within the 6 months prior to screening; Pleural effusion requiring drainage for symptom management within 28 days prior to screening; CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS; Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects.